HDR Gateway logo
HDR Gateway logo

Bookmarks

The clinical and economic burden of antibiotic use among paediatric patients with Varicella infection: a retrospective cohort analysis of real-world data in the UK

Safe People

Organisation name

Merck & Co. Inc

Organisation sector

Commercial

Applicant name(s)

Stephanie Kujawski - Chief Investigator - Merck & Co.Inc.Victoria Banks - Corresponding Applicant - Adelphi Real WorldAmisha Patel - Collaborator - Adelphi Real WorldCaroline Casey - Collaborator - Adelphi Real WorldChristina Diomatari - Collaborator - Adelphi Real WorldM.Nabi Kanibir - Collaborator - Merck & Co.Inc.Manjiri Pawaskar - Collaborator - Merck & Co. Inc - PennsylvaniaUSAOlivia Massey - Collaborator - Adelphi Real WorldTim Holbrook - Collaborator - Adelphi Real World

Safe Projects

Project ID

CPRD468

Lay summary

Varicella (more commonly known as chicken-pox) is a common, infectious disease that usually presents in childhood. Varicella causes an itchy, red rash across large portions of the body, along with headaches, tiredness and general feelings of illness. Although the majority of varicella cases resolve on their own, some patients can develop complications requiring treatment and in the most severe cases, hospitalisation.

Technical summary

Aim: To assess and characterize the use of antibiotics for the treatment and management of varicella and its associated complications in the paediatric population in the UK.

Latest approval date

07/04/2021

Safe Data

Dataset(s) name

HES Accident and Emergency

HES Admitted Patient Care

HES Outpatient

Patient Level Index of Multiple Deprivation

Safe Setting

Access type

Release